NCT04655625 is a Phase 2, PHASE3 clinical trial of Group A (AG0302-COVID19) in COVID-19, sponsored by AnGes, Inc..

Who is sponsoring NCT04655625?

NCT04655625 is sponsored by AnGes, Inc..

What drugs are being tested in NCT04655625?

Interventions in NCT04655625: Group A (AG0302-COVID19), Group A (Placebo), Group B (AG0302-COVID19), Group B (Placebo).

Is NCT04655625 still recruiting?

NCT04655625 is currently completed. Last updated 8 June 2022.

Last reviewed 2022-06-08 · How we verify

NCT04655625

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)

Completed Phase 2, PHASE3 Last updated 8 June 2022

What this trial tests

Phase 2, PHASE3 trial testing Group A (AG0302-COVID19) in COVID-19 in 500 participants. Completed in 1 February 2022.

Timeline

23 November 2020

Primary endpoint
2 April 2021

1 February 2022

Quick facts

Lead sponsor	AnGes, Inc.
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	500
Start date	23 November 2020
Primary completion	2 April 2021
Estimated completion	1 February 2022
Sites	8 locations across Japan

Drugs / interventions tested

Group A (AG0302-COVID19) — full drug profile →
Group A (Placebo)
Group B (AG0302-COVID19) — full drug profile →
Group B (Placebo)

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

AnGes, Inc. — full company profile →

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will assess the safety, immunogenicity and efficacy of AG0302-COVID19 in healthy adult volunteers.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape.
Tregoning JS, Flight KE, Higham SL, Wang Z, et al · · 2021 · cited 827× · PMID 34373623 · DOI 10.1038/s41577-021-00592-1
COVID-19 vaccine development: milestones, lessons and prospects.
Li M, Wang H, Tian L, Pang Z, et al · · 2022 · cited 298× · PMID 35504917 · DOI 10.1038/s41392-022-00996-y
COVID-19 vaccines: rapid development, implications, challenges and future prospects.
Kashte S, Gulbake A, El-Amin Iii SF, Gupta A. · · 2021 · cited 240× · PMID 33677814 · DOI 10.1007/s13577-021-00512-4
Efficacy and safety of COVID-19 vaccines.
Graña C, Ghosn L, Evrenoglou T, Jarde A, et al · · 2022 · cited 227× · PMID 36473651 · DOI 10.1002/14651858.cd015477
COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies.
Raman R, Patel KJ, Ranjan K. · · 2021 · cited 139× · PMID 34356617 · DOI 10.3390/biom11070993
An overview of current COVID-19 vaccine platforms.
Nagy A, Alhatlani B. · · 2021 · cited 113× · PMID 33936564 · DOI 10.1016/j.csbj.2021.04.061
COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials.
Yan ZP, Yang M, Lai CL. · · 2021 · cited 89× · PMID 33923054 · DOI 10.3390/ph14050406
A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges.
Rahman MM, Masum MHU, Wajed S, Talukder A. · · 2022 · cited 74× · PMID 35127995 · DOI 10.1007/s13337-022-00755-1

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other AnGes, Inc. trials

Trials by the same sponsor.

NCT04993586 — Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose) · Phase 1, PHASE2 · completed
NCT04527081 — Study of COVID-19 DNA Vaccine (AG0302-COVID19) · Phase 1, PHASE2 · completed
NCT04463472 — Study of COVID-19 DNA Vaccine (AG0301-COVID19) · Phase 1, PHASE2 · completed
NCT03263611 — AMG0103 in Subjects With Chronic Discogenic Lumbar Back Pain · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04655625 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AnGes, Inc.
Last refreshed: 8 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04655625.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing